stockportfolio.pro
Stocks / ADPT vs ARQT
ADPT vs ARQT
Adaptive Biotechnologies Corporation and Arcutis Biotherapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Adaptive Biotechnologies Corporation (ADPT) | Arcutis Biotherapeutics, Inc. (ARQT) | |
|---|---|---|
| Market cap | $3.0B | $3.0B |
| Revenue (latest FY) | $276.98M | $376.07M |
| Net income (latest FY) | $-59.50M | $-16.14M |
| Revenue growth (5y CAGR) | 23.0% | — |
| Net margin | -21.5% | -4.3% |
| Return on equity | -27.2% | -8.5% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ADPT — free Open ARQT — freeFrequently asked questions
Which is bigger, ADPT or ARQT?
Arcutis Biotherapeutics, Inc. is larger by market capitalization — $3.0B versus $3.0B.
Which grows faster, ADPT or ARQT?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.